Tvardi Therapeutics Inc
69C
Company Profile
Business description
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USAT: +1 713 489-8654
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,907.00 | 2.50 | 0.03% |
| CAC 40 | 8,170.09 | 0.00 | 0.00% |
| DAX 40 | 23,876.55 | 165.07 | -0.69% |
| Dow JONES (US) | 47,147.48 | 309.74 | -0.65% |
| FTSE 100 | 9,698.37 | 109.31 | -1.11% |
| HKSE | 26,572.46 | 500.57 | -1.85% |
| NASDAQ | 22,900.59 | 30.23 | 0.13% |
| Nikkei 225 | 50,376.53 | 905.30 | -1.77% |
| NZX 50 Index | 13,464.46 | 133.41 | -0.98% |
| S&P 500 | 6,734.11 | 3.38 | -0.05% |
| S&P/ASX 200 | 8,634.50 | 8.90 | 0.10% |
| SSE Composite Index | 3,990.49 | 39.01 | -0.97% |